Who’s Taking the Stage at Digital RESI November?

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

Next week’s digital partnering event, Redefining Early Stage Investments (RESI), taking place November 17-19, is fast-approaching! RESI conferences provide early-stage players powerful partnering opportunities, but go beyond traditional pitching and partnering by offering insightful expert investor panels. These panels pull back the curtain to what investors look for when sourcing assets and developing partnerships. RESI’s panels highlight key perspectives relevant to the early-stage life science and healthcare ecosystem.

Panel themes range from Corporate Venture Capital to Early Stage Therapeutics Investments and will provide deep insights on investor perspectives, how investors and strategic partners view the current landscape, and how fundraising entrepreneurs can effectively approach the right investors, among other topics.

Registered attendees can block off their calendars directly in the partnering platform to make sure they don’t miss a panel that fits their interest. If you haven’t yet registered and are interested in hearing from key industry players, it is still not too late to register! Sign up to start partnering and learning from these key players. We hope you’ll join us!

EARLY STAGE THERAPEUTICS INVESTORS

• Sascha Berger, Partner, TVM Capital Life Science
• Z Haroon, Chairman and General Partner, Julz Co LLC
• Sunil Shah, CEO, O2h Ventures
• Yaniv Sneor, Founding Member, Mid Atlantic Bio Angels
• Travis Whitfill, Partner, Bios Partners

DIAGNOSTICS INVESTORS

• Martin Pfister, Senior Investment Manager: Life Sciences, High-Tech Gründerfonds
• Diana Saraceni, Founder, Managing Director, Panakes Partners
• Noel Jee, Principal, Illumina Ventures
• Jorge Aquino, Director, Ventures, Johns Hopkins Technology Ventures
• Jorge Ramirez, Principal, H.I.G. BioHealth Partners

MEDICAL DEVICE INVESTORS

• Flora Yao, Founding Partner, Ivy Elite Capital
• George Li, Managing Partner, Proxima Ventures
• Gary Gershony, Medical Device Committee, Life Science Angels
• Rachel Rea, Director, Strategy & Portfolio Management, Surgical Innovations, Medtronic
• Mishael Zohar, Associate, OrbiMed Advisors LLC

DIGITAL HEALTH

• Ute Mercker, Investment Director, IBB Ventures
• Terri Mead, Founder, Class Bravo Ventures
• Sven Dethlefs, EVP Global Marketing & Portfolio, Teva Pharmaceuticals Industries
• Sean Cheng, Senior Investment Manager, Philips Health Technology Ventures
• Richard Proscia, Senior Associate, Providence Ventures

BIG PHARMA

• Ravi Ramadas, Director, Immunology External Innovation, Global BD&L, Sanofi
• Lisa Mendoza, Director, External Research & Alliances, Open Innovation – Digital Technologies, Bayer
• Ronald Dorenbos, Founder and Managing Director, BioFrontline Ltd.
• Tim Luker, Senior Director, Emerging Technology & Innovation, Corporate Business Development, Eli Lilly & Co

CORPORATE VENTURE CAPITAL

• Andy Merken, Partner, Corporate and Securities Co-Chair, Life Sciences, Burns & Levinson
• David Hwang, Managing Director, Early Stage Partnerships, Agilent Technologies
• Carrie Hurwitz Williams, Partner, McKesson Ventures
• Victor Stone, Partner, Takeda Ventures
• Hakan Goker, Vice President, Healthcare Team, M Ventures